Capital One initiated coverage of Jasper Therapeutics with an Overweight rating and $7 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JSPR:
- Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
- Is JSPR a Buy, Before Earnings?
- Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jasper Therapeutics appoints Carlos as SVP, Marcantonio as VP
- Jasper announces first patient dosed in Phase 1 trial of briquilimab